![]() |
|
|
Vol. 27, Issue 9, 1045-1056, September 1999
Drug Metabolism and Pharmacokinetics Section, DuPont
Pharmaceuticals Company, Stine-Haskell Research Center, Newark,
Delaware
Efavirenz (Sustiva) is a potent and specific inhibitor
of the HIV-1 reverse transcriptase and is approved for the treatment of
HIV infection. The metabolism of efavirenz in different species has
been described previously. Efavirenz is primarily metabolized in rats
to the glucuronide conjugate of 8-OH efavirenz. Electrospray ionization-liquid chromatography/mass spectrometry analyses of bile
samples from rats dosed with either efavirenz or with 8-OH efavirenz
revealed three polar metabolites, M9, M12, and M13, with
pseudomolecular ions [M-H]
at
m/z 733, 602, and 749, respectively. The
characteristic mass spectral fragmentation patterns obtained for
metabolites M9 and M13 suggested that these were glutathione-sulfate
diconjugates, and the presence of a glutathione moiety in metabolite M9
was confirmed by liquid chromatograpy/nuclear magnetic resonance (NMR) analysis of bile extracts. Metabolite M12 was characterized by liquid
chromatography/mass spectrometry as a glucuronide-sulfate diconjugate.
Unambiguous structures of M9, M12, and M13 were obtained from
one-dimensional proton and carbon NMR as well as proton-proton (correlated spectroscopy, two-dimensional shift correlation), proton-carbon heteronuclear multiple quantum correlation, and long-range proton-carbon (heteronuclear multiple bond correlation) correlated two-dimensional NMR analyses of metabolites isolated from
rat bile. The mass spectral and NMR analyses of M10, which was isolated
from rat urine, suggested a cysteinylglycine-sulfate diconjugate. The
isolation of these polar metabolites for further characterization by
NMR was aided by mass spectral analyses of HPLC fractions and solid
phase extraction extracts during the isolation steps. The complete
characterization of these novel diconjugates demonstrates that further
phase II metabolism of polar conjugates such as sulfates could take
place in vivo.
This article has been cited by other articles:
![]() |
H. Chen, W. Chen, L.-S. Gan, and A. E. Mutlib Metabolism of (S)-5,6-Difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Human Liver Microsomes. Metabolic Activation and Enzyme Kinetics Drug Metab. Dispos., January 1, 2003; 31(1): 122 - 132. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Fisher, D. Jackson, A. Kaerner, S. A. Wrighton, and A. G. Borel Characterization by Liquid Chromatography-Nuclear Magnetic Resonance Spectroscopy and Liquid Chromatography-Mass Spectrometry of Two Coupled Oxidative-Conjugative Metabolic Pathways for 7-Ethoxycoumarin in Human Liver Microsomes Treated with Alamethicin Drug Metab. Dispos., March 1, 2002; 30(3): 270 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Jaggi, R. S. Addison, A. R. King, B. D. Suthers, and R. G. Dickinson Conjugation of Desmethylnaproxen in the Rat---A Novel Acyl Glucuronide-Sulfate Diconjugate as a Major Biliary Metabolite Drug Metab. Dispos., February 1, 2002; 30(2): 161 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Mutlib, J. Shockcor, R. Espina, N. Graciani, A. Du, and L.-S. Gan Disposition of Glutathione Conjugates in Rats by a Novel Glutamic Acid Pathway: Characterization of Unique Peptide Conjugates by Liquid Chromatography/Mass Spectrometry and Liquid Chromatography/NMR J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 735 - 745. [Abstract] [Full Text] |
||||
![]() |
A. E. Mutlib, H. Chen, G. A. Nemeth, J. A. Markwalder, S. P. Seitz, L. S. Gan, and D. D. Christ Identification and Characterization of Efavirenz Metabolites by Liquid Chromatography/Mass Spectrometry and High Field NMR: Species Differences in the Metabolism of Efavirenz Drug Metab. Dispos., November 1, 1999; 27(11): 1319 - 1333. [Abstract] [Full Text] |
||||